Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ 880	$ (1,031,559)	$ 175,065
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	2,011	1,575	1,418
Loss on disposal of property and equipment	75		2
Share-based compensation expense	29,850	32,005	27,048
Change in fair value of note hedge warrants		(19)	(182)
Non-cash interest expense	1,904	2,060	1,853
Acquired in-process research and development		1,095,449
Deferred income taxes	68,090	72,637	65,739
Changes in assets and liabilities:
Accounts receivable, net	47,236	924	7,993
Prepaid expenses and other current assets	89	4,220	3,224
Operating lease right-of-use assets	1,558	1,437	1,327
Other assets	(854)	(319)	153
Accounts payable and accrued expenses	(20,208)	12,380	(8,116)
Accrued research and development costs	(14,650)	(5,875)	(10,638)
Operating lease liabilities	(2,176)	(1,995)	(1,947)
Other liabilities	(10,256)	507	10,824
Net cash provided by operating activities	103,549	183,427	273,763
Cash flows from investing activities:
Purchases of property and equipment	(142)	(273)	(136)
Acquisition of VectivBio Holding AG, net of cash acquired		(1,026,045)
Net cash used in investing activities	(142)	(1,026,318)	(136)
Cash flows from financing activities:
Proceeds from exercise of stock options and employee stock purchase plan	11,013	6,357	9,540
Taxes paid related to net share settlement of share-based awards	(737)
Purchase of subsidiary shares from noncontrolling interests		(26,311)
Repayment of 2022 Convertible Notes	(200,000)		(120,699)
Repurchases of common stock			(126,394)
Proceeds from revolving credit facility	150,000	400,000
Costs associated with revolving credit facility	(2,246)	(2,886)
Repayments of revolving credit facility	(65,000)	(100,000)
Net cash provided by (used in) financing activities	(106,970)	277,160	(237,553)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(32)	(53)
Net increase (decrease) in cash, cash equivalents and restricted cash	(3,595)	(565,784)	36,074
Cash, cash equivalents and restricted cash, beginning of period	92,154	657,938	621,864
Cash, cash equivalents and restricted cash, end of period	88,559	92,154	657,938
Supplemental cash flow disclosure:
Cash paid for interest	32,563	13,552	5,745
Cash paid for income taxes	$ 8,408	$ 9,945	4,615
Non-cash investing and financing activities
Stock option exercise proceeds receivable in other current assets			$ 2,351